Company Presentation

Acthera Therapeutics is developing a unique type of mechano-sensitive Hard-Shelled Liposomes (HSL), based on a patented synthetic lipid. The HSL release their payload when submitted to a determined level of pressure, which can be generated by various triggers. This allows a controlled and targeted delivery and enables the optimization of efficacy and safety of multiple drugs, from small molecules to RNA and peptides. Acthera is currently launching a Seed B funding round.